IRIDEX Corp(IRIX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.21 | Insider Own | 38.84% | Shs Outstand | 17.4M | Perf Week | -5.97% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 100% | Insider Trans | 21.87% | Shs Float | 10.7M | Perf Month | 0.87% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.04 | Inst Own | 17.36% | Short Float | 0.71% | Perf Quarter | -17.55% |
| Income | -0.00B | P/S | 0.24 | EPS this Y | 53.85% | Inst Trans | -0.4% | Short Ratio | 0.2 | Perf Half Y | -33.71% |
| Sales | 0.05B | P/B | - | EPS next 5Y | - | ROA | -12.06% | Short Interest | 0.08M | Perf YTD | -38.95% |
| Book/sh | -0.14 | P/C | 2.61 | EPS past 3/5Y | 17.9% 10.54% | ROE | -73.15% | 52W High | -57.77% ($1.65) | Perf Year | -34.95% |
| Cash/sh | 0.27 | P/FCF | - | Sales past 3/5Y | -2.58% 7.7% | ROIC | -47.22% | 52W Low | 14.66% ($0.61) | Perf 3Y | -70.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 36.91% | Gross Margin | 35.31% | Volatility(W/M) | 6.82% 11.6% | Perf 5Y | -91.99% |
| Dividend TTM | - | EV/Sales | 0.34 | Sales Y/Y TTM | 3.68% | Oper. Margin | -5.39% | ATR (14) | 0.06 | Perf 10Y | -94.76% |
| Dividend Ex-Date | - | Quick Ratio | 1.08 | EPS Q/Q | -22.8% | Profit Margin | -6.88% | RSI (14) | 40.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.82 | Sales Q/Q | -7.41% | SMA20 | -11.9% ($0.79) | Beta | 0.62 | Target Price | $2.75 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/8/18 | SMA50 | -2.83% ($0.72) | Rel Volume | 0.1 | Prev Close | $0.72 |
| Employees | 93 | LT Debt/Eq | 1.06 | EPS/Sales Surpr. | -600% -7.51% | SMA200 | -32.59% ($1.04) | Avg Volume(3M) | 0.39M | Price | $0.7 |
| IPO | 1996/2/16 | Option/Short | Yes/Yes | Trades | 130 | Volume | 40,242 | Change | -3.53% |
👁️ A small medical device company that supplies dedicated ophthalmic laser equipment and single-use probes used to treat glaucoma, retinal conditions, and diabetic retinopathy. Its flagship product, the Cyclo G6® glaucoma laser, combined with its retinal laser portfolio, anchors a "razor-and-blade" business model that pairs equipment sales with recurring revenue from consumables.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 10% of its average volume.
IRIX has a sound balance sheet but weak earning power
Of every $100 in sales, $5.39 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $24. Peers typically go for $145.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #117 of 140 in the industry
Based on market cap of $12M.
FAQ
What kind of company is IRIX?
IRIX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IRIX?
The market cap of IRIX is approximately $12M, ranking 5,371 within its sector.
What is the 52-week high and low for IRIX?
IRIX has recorded a 52-week high of $1.65 and a low of $0.61.
